Published in Blood Cancer J on July 29, 2016
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood (2016) 0.81
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J (2017) 0.75
Treatment of newly diagnosed myeloma: Bortezomib-based triplet. Semin Oncol (2016) 0.75
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc (2017) 0.75
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals (Basel) (2017) 0.75
Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget (2017) 0.75
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget (2017) 0.75
Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells. Oncotarget (2017) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol (2014) 4.37
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol (2014) 3.62
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol (1998) 3.41
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia (2013) 3.08
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol (2015) 2.44
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood (2013) 1.85
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol (2014) 1.39
Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res (2008) 1.33
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood (2010) 1.25
Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther (2010) 1.14
Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res (2014) 1.13
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood (2014) 1.12
Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J (2015) 1.01
Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol Cancer Ther (2013) 0.94
Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol (2013) 0.93
Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia (2015) 0.92
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev (2016) 0.91
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Invest New Drugs (2015) 0.89
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia (2015) 0.87
Targeting the Pim kinases in multiple myeloma. Blood Cancer J (2015) 0.84
Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38. Cancer J (2016) 0.84
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood (2016) 0.82
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene (2015) 0.80
MYC dysregulation in the progression of multiple myeloma. Leukemia (2019) 1.38
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood (2014) 1.12
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer J (2015) 0.79
Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia (2015) 0.75
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J (2016) 0.75
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood (2016) 0.75
The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplant (2016) 0.75
Blind men and an elephant. Blood (2015) 0.75
Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial. Leukemia (2017) 0.75
Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer J (2017) 0.75
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia (2017) 0.75
Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol (2017) 0.75
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer J (2020) 0.75
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J (2017) 0.75
Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes. Bone Marrow Transplant (2020) 0.75
Checking in: T cells against multiple myeloma. Blood (2017) 0.75
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol (2017) 0.75
Immune-based therapies in the management of multiple myeloma. Blood Cancer J (2020) 0.75
Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. Leuk Lymphoma (2017) 0.75